Cargando…
COVID-19 relapse associated with SARS-CoV-2 evasion from CD4(+) T-cell recognition in an agammaglobulinemia patient
A 25-year-old patient with a primary immunodeficiency lacking immunoglobulin production experienced a relapse after a 239-day period of persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Viral genetic sequencing demonstrated that SARS-CoV-2 had evolved during the infe...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116114/ https://www.ncbi.nlm.nih.gov/pubmed/37124420 http://dx.doi.org/10.1016/j.isci.2023.106685 |
_version_ | 1785028353939472384 |
---|---|
author | Morita, Ryo Kubota-Koketsu, Ritsuko Lu, Xiuyuan Sasaki, Tadahiro Nakayama, Emi E. Liu, Yu-chen Okuzaki, Daisuke Motooka, Daisuke Wing, James Badger Fujikawa, Yasunori Ichida, Yuji Amo, Kiyoko Goto, Tetsushi Hara, Junichi Shirano, Michinori Yamasaki, Sho Shioda, Tatsuo |
author_facet | Morita, Ryo Kubota-Koketsu, Ritsuko Lu, Xiuyuan Sasaki, Tadahiro Nakayama, Emi E. Liu, Yu-chen Okuzaki, Daisuke Motooka, Daisuke Wing, James Badger Fujikawa, Yasunori Ichida, Yuji Amo, Kiyoko Goto, Tetsushi Hara, Junichi Shirano, Michinori Yamasaki, Sho Shioda, Tatsuo |
author_sort | Morita, Ryo |
collection | PubMed |
description | A 25-year-old patient with a primary immunodeficiency lacking immunoglobulin production experienced a relapse after a 239-day period of persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Viral genetic sequencing demonstrated that SARS-CoV-2 had evolved during the infection period, with at least five mutations associated with host cellular immune recognition. Among them, the T32I mutation in ORF3a was found to evade recognition by CD4(+) T cells. The virus found after relapse showed an increased proliferative capacity in vitro. SARS-CoV-2 may have evolved to evade recognition by CD4(+) T cells and increased in its proliferative capacity during the persistent infection, likely leading to relapse. These mutations may further affect viral clearance in hosts with similar types of human leukocyte antigens. The early elimination of SARS-CoV-2 in immunocompromised patients is therefore important not only to improve the condition of patients but also to prevent the emergence of mutants that threaten public health. |
format | Online Article Text |
id | pubmed-10116114 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-101161142023-04-20 COVID-19 relapse associated with SARS-CoV-2 evasion from CD4(+) T-cell recognition in an agammaglobulinemia patient Morita, Ryo Kubota-Koketsu, Ritsuko Lu, Xiuyuan Sasaki, Tadahiro Nakayama, Emi E. Liu, Yu-chen Okuzaki, Daisuke Motooka, Daisuke Wing, James Badger Fujikawa, Yasunori Ichida, Yuji Amo, Kiyoko Goto, Tetsushi Hara, Junichi Shirano, Michinori Yamasaki, Sho Shioda, Tatsuo iScience Article A 25-year-old patient with a primary immunodeficiency lacking immunoglobulin production experienced a relapse after a 239-day period of persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Viral genetic sequencing demonstrated that SARS-CoV-2 had evolved during the infection period, with at least five mutations associated with host cellular immune recognition. Among them, the T32I mutation in ORF3a was found to evade recognition by CD4(+) T cells. The virus found after relapse showed an increased proliferative capacity in vitro. SARS-CoV-2 may have evolved to evade recognition by CD4(+) T cells and increased in its proliferative capacity during the persistent infection, likely leading to relapse. These mutations may further affect viral clearance in hosts with similar types of human leukocyte antigens. The early elimination of SARS-CoV-2 in immunocompromised patients is therefore important not only to improve the condition of patients but also to prevent the emergence of mutants that threaten public health. Elsevier 2023-04-20 /pmc/articles/PMC10116114/ /pubmed/37124420 http://dx.doi.org/10.1016/j.isci.2023.106685 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Morita, Ryo Kubota-Koketsu, Ritsuko Lu, Xiuyuan Sasaki, Tadahiro Nakayama, Emi E. Liu, Yu-chen Okuzaki, Daisuke Motooka, Daisuke Wing, James Badger Fujikawa, Yasunori Ichida, Yuji Amo, Kiyoko Goto, Tetsushi Hara, Junichi Shirano, Michinori Yamasaki, Sho Shioda, Tatsuo COVID-19 relapse associated with SARS-CoV-2 evasion from CD4(+) T-cell recognition in an agammaglobulinemia patient |
title | COVID-19 relapse associated with SARS-CoV-2 evasion from CD4(+) T-cell recognition in an agammaglobulinemia patient |
title_full | COVID-19 relapse associated with SARS-CoV-2 evasion from CD4(+) T-cell recognition in an agammaglobulinemia patient |
title_fullStr | COVID-19 relapse associated with SARS-CoV-2 evasion from CD4(+) T-cell recognition in an agammaglobulinemia patient |
title_full_unstemmed | COVID-19 relapse associated with SARS-CoV-2 evasion from CD4(+) T-cell recognition in an agammaglobulinemia patient |
title_short | COVID-19 relapse associated with SARS-CoV-2 evasion from CD4(+) T-cell recognition in an agammaglobulinemia patient |
title_sort | covid-19 relapse associated with sars-cov-2 evasion from cd4(+) t-cell recognition in an agammaglobulinemia patient |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116114/ https://www.ncbi.nlm.nih.gov/pubmed/37124420 http://dx.doi.org/10.1016/j.isci.2023.106685 |
work_keys_str_mv | AT moritaryo covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient AT kubotakoketsuritsuko covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient AT luxiuyuan covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient AT sasakitadahiro covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient AT nakayamaemie covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient AT liuyuchen covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient AT okuzakidaisuke covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient AT motookadaisuke covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient AT wingjamesbadger covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient AT fujikawayasunori covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient AT ichidayuji covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient AT amokiyoko covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient AT gototetsushi covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient AT harajunichi covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient AT shiranomichinori covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient AT yamasakisho covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient AT shiodatatsuo covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient |